On November 3, 1906, the German clinical psychiatrist and neuroanatomist Alois Alzheimer reported “A...
Insights
Sep 25, 2025
How Can You Diagnose Alzheimer's at the Earliest Stages?
Diagnosing Alzheimer’s at the earliest stages
An early Alzheimer’s diagnosis has never been more important — or more attainable — than it is today...
Aug 27, 2025
The Future of Alzheimer's Disease Diagnosis
What is the future of Alzheimer's disease diagnosis?
Two anti-amyloid drugs are now available to patients with mild cognitive impairment (MCI) or mild...
Jun 25, 2025
Everything You Need to Know About Amyloid Presence and Alzheimer’s Disease-modifying Therapies
Confirming amyloid pathology before administering Alzheimer’s disease-modifying therapies.
Approximately seven million Americans are currently living...
May 20, 2025
Video - The Scientist Symposium: Understanding Disease Through Biomarkers
The Evolution of AD Diagnosis: The Role of Biomarkers
Biomarkers are transforming the landscape of disease detection and diagnosis—especially in the...
May 8, 2025
Modern Alzheimer’s Diagnosis: What Clinicians Need to Know About Biomarkers and Staging
What PET scans, CSF assays, and blood tests reveal about Alzheimer’s — and how the A/T/N framework supports earlier, more accurate diagnoses.
Alzheimer...
Nov 13, 2024
Video - The Balancing Act: Alzheimer's Awareness Redefined
Better Weapons to Fight Alzheimer’s Disease
Mar 7, 2023
Video - A Neurochemist's Search to Save Memories - Christa's and Charlotte's Story About Alzheimer's Disease
Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, who was diagnosed with Alzheimer's disease in...
Nov 29, 2022
Scientific Poster - In an Optimized CSF Collection Protocol the pTau181/Aβ1-42 Ratio Increases Preanalytical Variability Over Measuring Aβ1-42 Alone
Background
Core cerebrospinal fluid (CSF) biomarker concentrations for β-amyloid1-42 (Aβ1-
42), β-amyloid1-40 (Aβ1-40), and pTau181 are valuable in...
Oct 14, 2022
Scientific Poster - Prediction of Amyloid PET Status Using the Lumipulse G β Amyloid Ratio (1-42/1-40)
Background
Cerebrospinal fluid ( amyloid biomarker concentrations are valuable
in the assessment of patients for Alzheimer’s dementia ( Automated...